# A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers

> **NCT00813241** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** celecoxib reference formulation
- **DRUG:** celecoxib test formulation A1
- **DRUG:** celecoxib test formulation B2
- **DRUG:** celecoxib test formulation C1

## Key facts

- **NCT ID:** NCT00813241
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813241, "A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00813241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*